Back to search

Peptide record

TPDB13094

Antibacterial Anticancer Antiparasitic Hemolysis Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB13094
Antibacterial Anticancer Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia CancerPPD 2.0 dbACP dbAMP 3.0 Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 18-aa standard natural multi-activity (Antibacterial, Anticancer, Antiparasitic, and other sources) peptide sequence curated from AntiBP3, Peptipedia, CancerPPD 2.0, and other sources, with an available 3D structural model.
Sequence
FIGTLIPLALGALTKLFK
Physicochemical Analysis
C95H158N20O21
RNDCEQHMSWYV
L
1916.42
10.60
2
0
11
+2
-3.29
1.422
162.78
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
2
Residue Composition
number
2
A
0
R
0
N
0
D
0
C
0
E
0
Q
2
G
0
H
2
I
5
L
2
K
0
M
2
F
1
P
0
S
2
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 2 L: 5 K: 2 M: 0 F: 2 P: 1 S: 0 T: 2 W: 0 Y: 0 V: 0
Chemical Descriptors
18
C95H158N20O21
1916.42
10.60
+2
-3.29
1.422
Evidence Records 19 records
Evidence 1 Activity

Activity

MIC
Antibacterial
8 µM

Target

Enterococcus faecalis ATCC 29212

Source & Reference

NA

Other

Active against bacteria and parasites. Inhibits Gram+ E. faecalis ATCC 29212 (MIC 8 uM), S. aureus ATCC 25923 (MIC 4 uM), S. epidermidis ATCC 12228 (MIC 2 uM), E. casseliflavus
Evidence 2 Activity

Activity

MIC
Antibacterial
4 µM

Target

Staphylococcus aureus ATCC 25923

Source & Reference

NA

Other

Active against bacteria and parasites. Inhibits Gram+ E. faecalis ATCC 29212 (MIC 8 uM), S. aureus ATCC 25923 (MIC 4 uM), S. epidermidis ATCC 12228 (MIC 2 uM), E. casseliflavus ATCC 700327 (MIC 16 uM), Gram- E.
Evidence 3 Activity

Activity

MIC
Antibacterial
2 µM

Target

Staphylococcus epidermidis ATCC 12228

Source & Reference

NA

Other

sites. Inhibits Gram+ E. faecalis ATCC 29212 (MIC 8 uM), S. aureus ATCC 25923 (MIC 4 uM), S. epidermidis ATCC 12228 (MIC 2 uM), E. casseliflavus ATCC 700327 (MIC 16 uM), Gram- E. coli ATCC 25922 (MIC 16 uM), K. pneum
Evidence 4 Activity

Activity

MIC
Antibacterial
16 µM

Target

E. casseliflavus ATCC 700327

Source & Reference

NA

Other

29212 (MIC 8 uM), S. aureus ATCC 25923 (MIC 4 uM), S. epidermidis ATCC 12228 (MIC 2 uM), E. casseliflavus ATCC 700327 (MIC 16 uM), Gram- E. coli ATCC 25922 (MIC 16 uM), K. pneumoniae ATCC 13883 (MIC 4 uM), and parasite
Evidence 5 Activity

Activity

MIC
Antibacterial
16 µM

Target

Escherichia coli ATCC 25922

Source & Reference

NA

Other

M), S. epidermidis ATCC 12228 (MIC 2 uM), E. casseliflavus ATCC 700327 (MIC 16 uM), Gram- E. coli ATCC 25922 (MIC 16 uM), K. pneumoniae ATCC 13883 (MIC 4 uM), and parasite T. cruzi (IC50 15.9 uM). It also inhib
Evidence 6 Activity

Activity

MIC
Antibacterial
4 µM

Target

Klebsiella pneumoniae ATCC 13883

Source & Reference

NA

Other

IC 2 uM), E. casseliflavus ATCC 700327 (MIC 16 uM), Gram- E. coli ATCC 25922 (MIC 16 uM), K. pneumoniae ATCC 13883 (MIC 4 uM), and parasite T. cruzi (IC50 15.9 uM). It also inhibits cancer cell proliferation (NIH/3T
Evidence 7 Activity

Activity

IC50
Antibacterial
15.9 µM

Target

T. cruzi

Source & Reference

NA

Other

, Gram- E. coli ATCC 25922 (MIC 16 uM), K. pneumoniae ATCC 13883 (MIC 4 uM), and parasite T. cruzi (IC50 15.9 uM). It also inhibits cancer cell proliferation (NIH/3T3, B16F10 cells, MCF-7 cells, and HeLa
Evidence 8 Activity

Activity

MIC
Antiparasitic
8 µM

Target

Enterococcus faecalis ATCC 29212

Source & Reference

dbAMP 3.0

Other

Source Activity Label Source Definition
Antiparasitic
dbAMP 3.0 classified under the Anti-parasitic function class.
Active against bacteria and parasites. Inhibits Gram+ E. faecalis ATCC 29212 (MIC 8 uM), S. aureus ATCC 25923 (MIC 4 uM), S. epidermidis ATCC 12228 (MIC 2 uM), E. casseliflavus
Evidence 9 Activity

Activity

MIC
Antiparasitic
4 µM

Target

Staphylococcus aureus ATCC 25923

Source & Reference

dbAMP 3.0

Other

Active against bacteria and parasites. Inhibits Gram+ E. faecalis ATCC 29212 (MIC 8 uM), S. aureus ATCC 25923 (MIC 4 uM), S. epidermidis ATCC 12228 (MIC 2 uM), E. casseliflavus ATCC 700327 (MIC 16 uM), Gram- E.
Evidence 10 Activity

Activity

MIC
Antiparasitic
2 µM

Target

Staphylococcus epidermidis ATCC 12228

Source & Reference

dbAMP 3.0

Other

sites. Inhibits Gram+ E. faecalis ATCC 29212 (MIC 8 uM), S. aureus ATCC 25923 (MIC 4 uM), S. epidermidis ATCC 12228 (MIC 2 uM), E. casseliflavus ATCC 700327 (MIC 16 uM), Gram- E. coli ATCC 25922 (MIC 16 uM), K. pneum
Evidence 11 Activity

Activity

MIC
Antiparasitic
16 µM

Target

E. casseliflavus ATCC 700327

Source & Reference

dbAMP 3.0

Other

29212 (MIC 8 uM), S. aureus ATCC 25923 (MIC 4 uM), S. epidermidis ATCC 12228 (MIC 2 uM), E. casseliflavus ATCC 700327 (MIC 16 uM), Gram- E. coli ATCC 25922 (MIC 16 uM), K. pneumoniae ATCC 13883 (MIC 4 uM), and parasite
Evidence 12 Activity

Activity

MIC
Antiparasitic
16 µM

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP 3.0

Other

M), S. epidermidis ATCC 12228 (MIC 2 uM), E. casseliflavus ATCC 700327 (MIC 16 uM), Gram- E. coli ATCC 25922 (MIC 16 uM), K. pneumoniae ATCC 13883 (MIC 4 uM), and parasite T. cruzi (IC50 15.9 uM). It also inhib
Evidence 13 Activity

Activity

MIC
Antiparasitic
4 µM

Target

Klebsiella pneumoniae ATCC 13883

Source & Reference

dbAMP 3.0

Other

IC 2 uM), E. casseliflavus ATCC 700327 (MIC 16 uM), Gram- E. coli ATCC 25922 (MIC 16 uM), K. pneumoniae ATCC 13883 (MIC 4 uM), and parasite T. cruzi (IC50 15.9 uM). It also inhibits cancer cell proliferation (NIH/3T
Evidence 14 Activity

Activity

IC50
Antiparasitic
15.9 µM

Target

T. cruzi

Source & Reference

dbAMP 3.0

Other

, Gram- E. coli ATCC 25922 (MIC 16 uM), K. pneumoniae ATCC 13883 (MIC 4 uM), and parasite T. cruzi (IC50 15.9 uM). It also inhibits cancer cell proliferation (NIH/3T3, B16F10 cells, MCF-7 cells, and HeLa
Evidence 15 Activity

Activity

HC50
Hemolysis
10 µM
Human red blood cells: HC50 =10 µM (0.019 g/L) (testing time is 24 h)

Target

Human red blood cells

Source & Reference

Hemolytik PD_Hemolysis
DRAMP4
Antibiotics (Basel). 2020 Sep 21 9(9):625

Other

Source Activity Label Source Definition
Hemolysis
Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 16 Activity

Activity

50% Hemolysis
Toxicity
10 µM
Hemolytic Cytotoxic
50% Hemolysis | 10 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Figainin 1, a Novel Amphibian Skin Peptide with Antimicrobial and Antiproliferative Properties. | Antibiotics (Basel) | 2020
Evidence 17 Activity

Activity

IC50
Toxicity
13 µM
Cytotoxic
IC50 | 13 | µM | target cell: Mouse fibroblasts NIH 3T3

Target

Mouse fibroblasts NIH 3T3

Source & Reference

NA
DBAASP
Figainin 1, a Novel Amphibian Skin Peptide with Antimicrobial and Antiproliferative Properties. | Antibiotics (Basel) | 2020
Evidence 18 Activity

Activity

HC50
Toxicity
10 µM
Hemolytic Cytotoxic
Hemolytic_activity: Human red blood cells: HC50 =10 µM (0.019 g/L) (testing time is 24 h) | Cytotoxicity: NIH 3T3: IC50=13 µM (0.025 g/L) (testing time is 24 h)

Target

erythrocytes

Source & Reference

NA
DRAMP
Antibiotics (Basel). 2020 Sep 21 9(9):625
Evidence 19 Hemolysis

Activity

10 µM
HC50
Human red blood cells: HC50 =10 µM (0.019 g/L) (testing time is 24 h)
Hemolysis

Target

Human red blood cells

Source & Reference

PD_Hemolysis
Antibiotics (Basel). 2020 Sep 21 9(9):625
DRAMP4
PD_Hemolysis